Pharnext: listing suspended pending further update
This announcement comes after the biotech company had recently declared its intention to enter into a discussion with its shareholders regarding its situation and outlook.
Prior to this, the company had decided to embark on a drastic cost-cutting plan
Despite the publication of disappointing Phase III results in Charcot disease earlier this year, Pharnext believes that there is an opportunity to gain approval for its lead drug candidate by demonstrating a favorable safety profile and possible benefit on certain clinical endpoints.
I am aware of the complexity of our situation and the multiplication of recent announcements", says Hugo Brugière, Pharnext's Managing Director, in a press release.
"I therefore feel it is necessary to provide the financial community with a complete summary in a press release to be published very shortly", he adds.
For the record, the share has lost over 81% of its value since the start of the year.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction